Talecris Biotherapeutics closes initial public offering of common stock

Talecris Biotherapeutics Holdings Corp. (NASDAQ:TLCR) (“Talecris” or the “Company”) today announced the closing on October 6 of its initial public offering of shares of common stock, which was priced on September 30 at a public offering price of $19.00 per share.

In connection with the initial public offering, the underwriters exercised in full their option to purchase an additional 6,000,000 shares of common stock from the selling stockholder, Talecris Holdings, LLC. Talecris Holdings LLC is owned by Cerberus-Plasma Holdings, LLC, the managing member of which is Cerberus Partners, L.P., and by limited partnerships affiliated with Ampersand Ventures. As a result, a total of 56,000,000 shares were sold in the initial public offering, consisting of 28,947,368 shares by the Company and 27,052,632 shares by the selling stockholder. Net proceeds received by the Company were used to pay down debt. The Company did not receive any proceeds from the sale of shares by the selling stockholder.

Morgan Stanley & Co. Incorporated, Goldman, Sachs & Co., Citigroup Global Markets Inc. and J.P. Morgan Securities Inc. acted as joint book-running managers for the offering. Wells Fargo Securities, LLC, Barclays Capital Inc. and UBS Investment Bank acted as co-managers. Reed Smith LLP acted as legal counsel to Talecris.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on September 30, 2009. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any such offer or solicitation or any sale of securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.